ClinicalTrials.gg
CompletedNCT00879333GRANITE-1Updated Nov 3, 2015Results posted

Safety and Efficacy of RAD001 (Everolimus) Monotherapy Plus Best Supportive Care in Patients With Advanced Gastric Cancer (AGC)

A Phase 3 interventional study of Everolimus and Everolimus placebo in Advanced Gastric Cancer, sponsored by Novartis Pharmaceuticals. Completed at 122 sites in 22 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-11-03.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
656
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 13 studies testing everolimus in Stomach Neoplasms — none open to participants now, none under way, none of them phase 3. Everolimus · Stomach Neoplasms.

Enrollment
Largest of 13
656 · median 49
Started
2009
with 2 others
Phase 3
2 of 13
none open now
Registered
4th of 13
by date
Lead sponsor
3 of 13
Novartis Pharmaceuticals

Among the 13 studies testing everolimus in Stomach Neoplasms, this one has the largest enrollment, is one of 3 that started in 2009, is one of 2 in phase 3, and was the 4th registered.

Stomach Neoplasms

3,406 studies on the registry are indexed under Stomach Neoplasms; 995 are open to participants now.

Browse Stomach Neoplasms studies →

Open to participants now

None of the 13 studies testing everolimus in Stomach Neoplasms is open now. The open studies under Stomach Neoplasms, anywhere →

About everolimus

Everolimus: first FDA approval 2009 (AFINITOR), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 704 Stomach Neoplasms studies recruiting now, 376 (53%) set no upper age limit and 194 (28%) stop at 75 or younger; 28 take children under 18; 70 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 13 studies testing everolimus in Stomach Neoplasms as a file.
02

Study summary

This study is designed to assess the safety and efficacy of RAD001 monotherapy in patients with advanced gastric cancer which has progressed after one or two lines of prior chemotherapy.

03

Conditions studied

  • Advanced Gastric Cancer

Keywords

  • Gastric cancer,
  • advanced gastric cancer,
  • stomach neoplasm,
  • stomach disease,
  • adenocarcinoma of stomach,
  • GI neoplasm
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female patients > 18 years old
  • or cytologically confirmed and documented gastric adenocarcinoma
  • Documented progression after 1 or 2 prior chemotherapy treatments for advanced disease
  • Performance Status of \< 2
  • Lab parameters within specifically defined intervals
  • Able to provide written

Exclusion criteria

Exclusion Criteria:

  • Patients who have received > 2 prior systemic therapies for advanced disease
  • Administration of another anticancer therapy within 3 weeks prior to randomization
  • Chronic treatment with or another agent
  • Major surgery within 2 weeks prior to randomization
  • Patients with
  • Any other severe and/or uncontrolled medical condition

Other protocol-defined inclusion/exclusion criteria may apply

Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
656 participants (actual)

Study arms

  • Experimental
    Everolimus + BSC

    All patients were randomized to receive everolimus + BSC. All patients orally took two 5 mg tablets of everolimus once daily. Therefore, all patients in the everolimus arm took a total daily dose of 10 mg. Best supportive care was in accordance with the local practice of an individual institution or center, and specifically excluded anti-cancer treatments.

    Drug: Everolimus · Drug: Best Supportive Care (BSC)

  • Placebo comparator
    Placebo + BSC

    All patients were randomized to receive placebo + BSC. All patients orally took two 5 mg tablets of matching placebo once daily. Therefore, all patients in the placebo receive matching tablets of total daily dose of 10 mg. Best supportive care was in accordance with the local practice of an individual institution or center, and specifically excluded anti-cancer treatments.

    Drug: Everolimus placebo · Drug: Best Supportive Care (BSC)

Interventions

  • Everolimus was formulated as tablets of 5 mg strength. In both treatment arms, the study drug was given by continuous oral daily dosing of 10 mg (2 tablets x 5 mg) each morning.

    Also known as: RAD001

  • DrugEverolimus placebo

    Placebo was formulated to be indistinguishable from the everolimus tablets, also formulated as tablets of 5 mg strength. In both treatment arms, the study drug was given by continuous oral daily dosing of 10 mg (2 tablets x 5 mg) each morning.

  • DrugBest Supportive Care (BSC)

    Best supportive care is defined as care in accordance with the local practice of an individual institution or center, specifically excluding anti-cancer treatments.

06

What researchers measure

Primary outcomes

  1. Overall Survival (OS)

    The primary objective of this study was to compare OS between everolimus + best supportive care (BSC) and placebo + BSC. OS, was defined as the time from date of randomization to the date of death due to any cause. If at the analysis cut-off date a patient was not known to have died, survival was censored at the date of the last contact. OS was analyzed using the Kaplan Meier estimates method.

    Time frame: 2.5 years

Secondary outcomes

  1. Progression Free Survival (PFS)

    Progression free survival was defined as the time from the date of randomization to the date of the first documented disease progression or death due to any cause, where progression was based on Investigator assessment of baseline and post-baseline scans according to RECIST. Progression free survival was censored if no PFS event was observed before the first to occur out of (i) the cut-off date, or (ii) the date when a further anticancer therapy was started. The censoring date was the date of the last adequate tumor assessment before either of these two events occurred. If a PFS event was observed after two or more missing or non-evaluable tumor assessments, then the date of progression was censored at the date of the last adequate tumor assessment; for a PFS event observed after a single missing or non-evaluable tumor assessment, the actual date of disease progression was used. Anslsis was done using Kaplan-Meier estimates method.

    Time frame: 2.5 years

  2. Patient Reported Outcome (PRO): Time to Definitive Deterioration of European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire 30 (EORTC QLQ-C30) Scores

    The EORTC QLQ-C30 global health status/quality of life sub-scale (QL) was pre-specified as the primary domain of interest, followed by physical functioning (PF), social functioning (SF) and emotional functioning (EF).The EORTC QLQ-C30 questionnaire, along with a module specific for gastric cancer patients (EORTC QLQ-STO22), was used to evaluate PRO. The QLQ-C30 has five function scales (physical, role, cognitive, emotional and social), three symptom scales (fatigue, pain and nausea/vomiting) and a global health status/quality of life scale. In addition, there are questions that assess specific symptoms. The QLQ-STO22 consists of 22 questions that make up five multi-item scales (dysphagia, pain, reflux, eating and anxiety) and four single-item scales (dry mouth, tasting, body image and hair loss).

    Time frame: 2.5 years

  3. Time to Definitive Deterioration of Eastern Cooperative Oncology Group Performance Status (ECOG PS) Score

    The ECOG PS scale was used to classify patients according to their functional impairment, with scores ranging from 0 (fully active) to 5 (dead). An analysis of the time to definitive deterioration of the ECOG PS by one category of the score from baseline was performed. Definitive deterioration was defined as a definitive increase by one category from baseline in ECOG PS, with no later improvements observed during the course of the study. A single measure reporting an increase in ECOG PS is sufficient to consider it as a definitive worsening only if it was the last one available for the patient. Kaplan-Meier method was used to estimate the distribution function of time to definitive worsening.

    Time frame: 2.5 years

  4. Overall Response Rate (ORR)

    ORR was defined as the proportion of patients with measurable disease in whom best overall response (OR) was either complete response (CR) or partial response (PR) according to RECIST criteria.

    Time frame: 2.5 years

  5. Everolimus Steady State Concentraions at Predose (Cmin) and Cmax at Week 5

    Cmin is the minimum (trough) steady-state drug concentration in the blood during multiple dosing and Cmax is the maximum (peak) blood drug concentration after dose administration. Cmax is estimated as the maximum of C1h and C2H. C1h is 1 hour post-dose blood concentration and C2h is 2 hour post-dose blood concentration. Only valid pre-dose (Cmin), C1h, and C2h everolimus samples were included in the analysis. Valid pre-dose samples were confirmed blood samples collected at steady-state, collected immediately prior to dosing on the same study day, and collected at approximately 24 ± 4 hours after the previous dose and with no vomiting within the first 4 hours following the last dose. Valid C1h and C2h samples were confirmed blood samples collected at steady-state and within ± 1 hour window and with no vomiting within the first 4 hours following the current and previous dose.

    Time frame: Week 5

  6. Everolimus Steady State Concentraions at Predose (Cmin) and Cmax by Region Asia vs. Rest of the World (ROW) at Week 5

    Cmin is the minimum (trough) steady-state drug concentration in the blood during multiple dosing and Cmax is the maximum (peak) blood drug concentration after dose administration. Cmax is estimated as the maximum of C1h and C2H. C1h is 1 hour post-dose blood concentration and C2h is 2 hour post-dose blood concentration. Only valid pre-dose (Cmin), C1h, and C2h everolimus samples were included in the analysis. Valid pre-dose samples were confirmed blood samples collected at steady-state, collected immediately prior to dosing on the same study day, and collected at approximately 24 ± 4 hours after the previous dose and with no vomiting within the first 4 hours following the last dose. Valid C1h and C2h samples were confirmed blood samples collected at steady-state and within ± 1 hour window and with no vomiting within the first 4 hours following the current and previous dose.

    Time frame: Week 5

07

Results

Posted Apr 6, 2015
Limitations and caveats
4 randomized patients, 2 patients each from the everolimus and placebo arms were excluded from the safety analyses as they did not receive any dose of study treatment.

Participant flow

Participant flow — Overall Study
MilestoneEverolimus 10mg/DailyPlacebo
Started439217
Discontinued study treatment428217
Completed110
Not completed428217
Withdrew: Adverse event9434
Withdrew: Abnormal laboratory value10
Withdrew: Withdrawal by subject207
Withdrew: Lost to follow-up21
Withdrew: Administrative problems20
Withdrew: Death165
Withdrew: Disease progression292169
Withdrew: Protocol violation11

Outcome measures

PrimaryOverall Survival (OS)

The primary objective of this study was to compare OS between everolimus + best supportive care (BSC) and placebo + BSC. OS, was defined as the time from date of randomization to the date of death due to any cause. If at the analysis cut-off date a patient was not known to have died, survival was censored at the date of the last contact. OS was analyzed using the Kaplan Meier estimates method.

Time frame:
2.5 years
Reported as:
Median · Months
Overall Survival (OS)
MonthsEverolimus 10mg/DailyPlacebo
Overall Survival (OS)5.39 (4.80 to 6.01)4.34 (3.81 to 5.49)
SecondaryProgression Free Survival (PFS)

Progression free survival was defined as the time from the date of randomization to the date of the first documented disease progression or death due to any cause, where progression was based on Investigator assessment of baseline and post-baseline scans according to RECIST. Progression free survival was censored if no PFS event was observed before the first to occur out of (i) the cut-off date, or (ii) the date when a further anticancer therapy was started. The censoring date was the date of the last adequate tumor assessment before either of these two events occurred. If a PFS event was observed after two or more missing or non-evaluable tumor assessments, then the date of progression was censored at the date of the last adequate tumor assessment; for a PFS event observed after a single missing or non-evaluable tumor assessment, the actual date of disease progression was used. Anslsis was done using Kaplan-Meier estimates method.

Time frame:
2.5 years
Reported as:
Median · Months
Progression Free Survival (PFS)
MonthsEverolimus 10mg/DailyPlacebo
Progression Free Survival (PFS)1.68 (1.51 to 1.94)1.41 (1.38 to 1.45)
SecondaryPatient Reported Outcome (PRO): Time to Definitive Deterioration of European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire 30 (EORTC QLQ-C30) Scores

The EORTC QLQ-C30 global health status/quality of life sub-scale (QL) was pre-specified as the primary domain of interest, followed by physical functioning (PF), social functioning (SF) and emotional functioning (EF).The EORTC QLQ-C30 questionnaire, along with a module specific for gastric cancer patients (EORTC QLQ-STO22), was used to evaluate PRO. The QLQ-C30 has five function scales (physical, role, cognitive, emotional and social), three symptom scales (fatigue, pain and nausea/vomiting) and a global health status/quality of life scale. In addition, there are questions that assess specific symptoms. The QLQ-STO22 consists of 22 questions that make up five multi-item scales (dysphagia, pain, reflux, eating and anxiety) and four single-item scales (dry mouth, tasting, body image and hair loss).

Time frame:
2.5 years
Reported as:
Median · Months
Patient Reported Outcome (PRO): Time to Definitive Deterioration of European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire 30 (EORTC QLQ-C30) Scores
MonthsEverolimus 10mg/DailyPlacebo
In QL score by at least 5 % compared to baseline1.51 (1.28 to 1.84)1.45 (1.05 to 1.68)
In PF score by at least 5 % compared to baseline1.35 (1.12 to 1.54)1.15 (1.02 to 1.64)
In SF score by at least 5 % compared to baseline1.87 (1.84 to 2.30)1.87 (1.64 to 2.46)
In EF score by at least 5 % compared to baseline1.84 (1.61 to 2.10)1.71 (1.41 to 1.87)
SecondaryTime to Definitive Deterioration of Eastern Cooperative Oncology Group Performance Status (ECOG PS) Score

The ECOG PS scale was used to classify patients according to their functional impairment, with scores ranging from 0 (fully active) to 5 (dead). An analysis of the time to definitive deterioration of the ECOG PS by one category of the score from baseline was performed. Definitive deterioration was defined as a definitive increase by one category from baseline in ECOG PS, with no later improvements observed during the course of the study. A single measure reporting an increase in ECOG PS is sufficient to consider it as a definitive worsening only if it was the last one available for the patient. Kaplan-Meier method was used to estimate the distribution function of time to definitive worsening.

Time frame:
2.5 years
Reported as:
Median · Months
Time to Definitive Deterioration of Eastern Cooperative Oncology Group Performance Status (ECOG PS) Score
MonthsEverolimus 10mg/DailyPlacebo
Time to Definitive Deterioration of Eastern Cooperative Oncology Group Performance Status (ECOG PS) Score2.30 (1.97 to 2.79)2.23 (1.87 to 2.92)
SecondaryOverall Response Rate (ORR)

ORR was defined as the proportion of patients with measurable disease in whom best overall response (OR) was either complete response (CR) or partial response (PR) according to RECIST criteria.

Time frame:
2.5 years
Reported as:
Number · Participants
Overall Response Rate (ORR)
ParticipantsEverolimus 10mg/DailyPlacebo
Measurable Disease379191
Complete Response (CR)10
Partial Response (PR)164
Overall Response Rate (ORR)174
SecondaryEverolimus Steady State Concentraions at Predose (Cmin) and Cmax at Week 5

Cmin is the minimum (trough) steady-state drug concentration in the blood during multiple dosing and Cmax is the maximum (peak) blood drug concentration after dose administration. Cmax is estimated as the maximum of C1h and C2H. C1h is 1 hour post-dose blood concentration and C2h is 2 hour post-dose blood concentration. Only valid pre-dose (Cmin), C1h, and C2h everolimus samples were included in the analysis. Valid pre-dose samples were confirmed blood samples collected at steady-state, collected immediately prior to dosing on the same study day, and collected at approximately 24 ± 4 hours after the previous dose and with no vomiting within the first 4 hours following the last dose. Valid C1h and C2h samples were confirmed blood samples collected at steady-state and within ± 1 hour window and with no vomiting within the first 4 hours following the current and previous dose.

Time frame:
Week 5
Reported as:
Mean · ng/mL
Everolimus Steady State Concentraions at Predose (Cmin) and Cmax at Week 5
ng/mLEverolimus 10mg/DailyEverolimus 5 mg/Day
Pre-dose (Cmin) (n: 201,18)16.143 ± 10.772310.498 ± 6.1432
Cmax (n: 218,16)72.775 ± 36.543537.269 ± 27.2086
SecondaryEverolimus Steady State Concentraions at Predose (Cmin) and Cmax by Region Asia vs. Rest of the World (ROW) at Week 5

Cmin is the minimum (trough) steady-state drug concentration in the blood during multiple dosing and Cmax is the maximum (peak) blood drug concentration after dose administration. Cmax is estimated as the maximum of C1h and C2H. C1h is 1 hour post-dose blood concentration and C2h is 2 hour post-dose blood concentration. Only valid pre-dose (Cmin), C1h, and C2h everolimus samples were included in the analysis. Valid pre-dose samples were confirmed blood samples collected at steady-state, collected immediately prior to dosing on the same study day, and collected at approximately 24 ± 4 hours after the previous dose and with no vomiting within the first 4 hours following the last dose. Valid C1h and C2h samples were confirmed blood samples collected at steady-state and within ± 1 hour window and with no vomiting within the first 4 hours following the current and previous dose.

Time frame:
Week 5
Reported as:
Mean · ng/mL
Everolimus Steady State Concentraions at Predose (Cmin) and Cmax by Region Asia vs. Rest of the World (ROW) at Week 5
ng/mLEverolimus 10mg/DailyEverolimus 5mg/Day
Asia: Pre-dose (n:127, 11)16.804 ± 9.61639.921 ± 5.1565
Asia: Cmax (n:132, 10)73.568 ± 34.189834.580 ± 26.8110
Rest of the World: Pre-dose (n:74, 7)15.009 ± 12.500011.406 ± 7.8128
Rest of the World: Cmax (n:86, 6)71.558 ± 40.065541.750 ± 29.8074

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Everolimus 10mg / Daily—210/437 (48.1%)416/437 (95.2%)
Placebo—89/215 (41.4%)193/215 (89.8%)
Most frequent serious events
Showing 10 of 209
Most frequent serious events
EventEverolimus 10mg / DailyPlacebo
Abdominal painGastrointestinal disorders21/43712/215
Decreased appetiteMetabolism and nutrition disorders21/4378/215
VomitingGastrointestinal disorders14/43710/215
NauseaGastrointestinal disorders9/4379/215
AnaemiaBlood and lymphatic system disorders15/4372/215
General physical health deteriorationGeneral disorders14/4374/215
Gastrointestinal haemorrhageGastrointestinal disorders13/4373/215
AstheniaGeneral disorders12/4376/215
PneumoniaInfections and infestations12/4374/215
Intestinal obstructionGastrointestinal disorders5/4375/215
Most frequent other events
Showing 10 of 38
Most frequent other events
EventEverolimus 10mg / DailyPlacebo
Decreased appetiteMetabolism and nutrition disorders202/43776/215
StomatitisGastrointestinal disorders173/43722/215
FatigueGeneral disorders146/43763/215
NauseaGastrointestinal disorders129/43763/215
DiarrhoeaGastrointestinal disorders112/43733/215
VomitingGastrointestinal disorders98/43754/215
AnaemiaBlood and lymphatic system disorders108/43742/215
Abdominal painGastrointestinal disorders90/43749/215
ConstipationGastrointestinal disorders92/43741/215
Weight decreasedInvestigations87/43719/215

Baseline characteristics

Age, Continuous
Age, Continuous(years)Everolimus 10mg/DailyPlaceboTotal
Mean60.3 ± 11.5960.8 ± 11.6160.4 ± 11.59
Age, Customized
Age, Customized(Participants)Everolimus 10mg/DailyPlaceboTotal
< 65 years260129389
>=65 years17988267
Sex: Female, Male
Sex: Female, Male(Participants)Everolimus 10mg/DailyPlaceboTotal
Female11756173
Male322161483
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Everolimus 10mg/DailyPlaceboTotal
Caucasian16675241
Black314
Asian251126377
Native American011
Other191433
08

Study locations

122 sites
  • Highlands Oncology Group DeptofHighlandsOncologyGrp(2)
    Fayetteville, Arkansas 72703, United States
  • Loma Linda Oncology Medical Group Loma Linda
    Redlands, California 92374, United States
  • Henry Ford Hospital Dept. of Henry Ford Hospital
    Detroit, Michigan 48202-2689, United States
  • University of Minnesota Cancer Center
    Minneapolis, Minnesota 55455, United States
  • University of Texas Southwestern Medical Center DeptofSimmons Cancer Center(4)
    Dallas, Texas 75390-8527, United States
  • The Center for Cancer and Blood Disorders Dept. of The Ctr for C & BD(2)
    Fort Worth, Texas 76104, United States
  • University of Texas/MD Anderson Cancer Center Gastrointestinal Med. Oncology
    Houston, Texas 77030-4009, United States
  • University of Washington Cancer Care Seattle Cancer Alliance
    Seattle, Washington 98109-1023, United States
  • Novartis Investigative Site
    Buenos Aires, Buenos Aires C1264AAA, Argentina
  • Novartis Investigative Site
    Córdoba, Córdoba Province X5000IUG, Argentina
  • Novartis Investigative Site
    Rio Negro, Viedma 8500, Argentina
  • Novartis Investigative Site
    Canberra, Australian Capital Territory 2605, Australia
  • Novartis Investigative Site
    Herston, Queensland 4029, Australia
  • Novartis Investigative Site
    Kurralta Park, South Australia 5037, Australia
  • Novartis Investigative Site
    North Adelaide, South Australia 5006, Australia
  • Novartis Investigative Site
    Box Hill, Victoria 3128, Australia
  • Novartis Investigative Site
    Clayton, Victoria 3168, Australia
  • Novartis Investigative Site
    Footscray, Victoria 3011, Australia
  • Novartis Investigative Site
    Heidelberg, Victoria 3084, Australia
  • Novartis Investigative Site
    Prahran, Victoria 3181, Australia
  • Novartis Investigative Site
    Charleroi, 6000, Belgium
  • Novartis Investigative Site
    Ghent, 9000, Belgium
  • Novartis Investigative Site
    Leuven, 3000, Belgium
  • Novartis Investigative Site
    Liège, 4000, Belgium
  • Novartis Investigative Site
    North Vancouver, British Columbia V7L 2L7, Canada
  • Novartis Investigative Site
    Vancouver, British Columbia V5Z 4E6, Canada
  • Novartis Investigative Site
    Toronto, Ontario M4N 3M5, Canada
  • Novartis Investigative Site
    Toronto, Ontario M5B 1W8, Canada
  • Novartis Investigative Site
    Montreal, Quebec H3G 1A4, Canada
  • Novartis Investigative Site
    Sherbrooke, Quebec J1H 5N4, Canada
  • Novartis Investigative Site
    Guangzhou, Guangdong 510515, China
  • Novartis Investigative Site
    Shijiazhuang, Hebei 050011, China
  • Novartis Investigative Site
    Harbin, Heilongjiang 150081, China
  • Novartis Investigative Site
    Nanjing, Jiangsu 210002, China
  • Novartis Investigative Site
    Suzhou, Jiangsu 215006, China
  • Novartis Investigative Site
    Shenyang, Liaoning, China
  • Novartis Investigative Site
    Chengdu, Sichuan 610041, China
  • Novartis Investigative Site
    Hangzhou, Zhejiang 310016, China
  • Novartis Investigative Site
    Beijing, 100036, China
  • Novartis Investigative Site
    Beijing, 100039, China
  • Novartis Investigative Site
    Guangzhou, 510060, China
  • Novartis Investigative Site
    Shanghai, 200003, China
  • Novartis Investigative Site
    Shanghai, 200025, China
  • Novartis Investigative Site
    Shanghai, 200032, China
  • Novartis Investigative Site
    Poitiers, France 86000, France
  • Novartis Investigative Site
    Avignon, 84082, France
  • Novartis Investigative Site
    Clermont-Ferrand, 63003, France
  • Novartis Investigative Site
    Clichy, 92110, France
  • Novartis Investigative Site
    Dijon, 21079, France
  • Novartis Investigative Site
    Lyon, 69373, France
  • Novartis Investigative Site
    Marseille, 13385, France
  • Novartis Investigative Site
    Montpellier, 34298, France
  • Novartis Investigative Site
    Nice, 06189, France
  • Novartis Investigative Site
    Paris, 75015, France
  • Novartis Investigative Site
    Pessac, 33604, France
  • Novartis Investigative Site
    Reims, 51092, France
  • Novartis Investigative Site
    Rennes, 35062, France
  • Novartis Investigative Site
    Toulouse, 31054, France
  • Novartis Investigative Site
    Villejuif, 94805, France
  • Novartis Investigative Site
    Mannheim, Baden-Wurttemberg 68305, Germany
  • Novartis Investigative Site
    Mainz, Germany 55131, Germany
  • Novartis Investigative Site
    Berlin, 13353, Germany
  • Novartis Investigative Site
    Bielefeld, 33604, Germany
  • Novartis Investigative Site
    Frankfurt, 60488, Germany
  • Novartis Investigative Site
    München, 81675, Germany
  • Novartis Investigative Site
    Offenburg, 77652, Germany
  • Novartis Investigative Site
    Trier, 54290, Germany
  • Novartis Investigative Site
    Hong Kong SAR, Hong Kong
  • Novartis Investigative Site
    Jerusalem, 9112001, Israel
  • Novartis Investigative Site
    Petah Tikva, 49100, Israel
  • Novartis Investigative Site
    Ramat Gan, 5266202, Israel
  • Novartis Investigative Site
    Rehovot, 76100, Israel
  • Novartis Investigative Site
    Florence, FI 50134, Italy
  • Novartis Investigative Site
    Rozzano, MI 20089, Italy
  • Novartis Investigative Site
    Modena, MO 41100, Italy
  • Novartis Investigative Site
    Aviano, PN 33081, Italy
  • Novartis Investigative Site
    Frattamaggiore, 80020, Italy
  • Novartis Investigative Site
    Nagoya, Aichi-ken 464-8681, Japan
  • Novartis Investigative Site
    Kashiwa, Chiba 277-8577, Japan
  • Novartis Investigative Site
    Matsuyama, Ehime 791-0280, Japan
  • Novartis Investigative Site
    Fukuoka, Fukuoka 812-8582, Japan
  • Novartis Investigative Site
    Sapporo, Hokkaido 060-8648, Japan
  • Novartis Investigative Site
    Sagamihara, Kanagawa 252-0380, Japan
  • Novartis Investigative Site
    Sendai, Miyagi 980-8574, Japan
  • Novartis Investigative Site
    Sayama, Osaka 589-8511, Japan
  • Novartis Investigative Site
    Takatsuki, Osaka 569-8686, Japan
  • Novartis Investigative Site
    Kitaadachi-gun, Saitama 362-0806, Japan
  • Novartis Investigative Site
    Utsunomiya, Tochigi 320-0834, Japan
  • Novartis Investigative Site
    Chuo-ku, Tokyo 104-0045, Japan
  • Novartis Investigative Site
    Koto, Tokyo 135-8550, Japan
  • Novartis Investigative Site
    Mitaka, Tokyo 181-8611, Japan
  • Novartis Investigative Site
    León, Guanajuato 37000, Mexico
  • Novartis Investigative Site
    Mexico City, Mexico City 14080, Mexico
  • Novartis Investigative Site
    Amsterdam, 1105 AZ, Netherlands
  • Novartis Investigative Site
    Auckland, New Zealand
  • Novartis Investigative Site
    San Borja, Lima region 41, Peru
  • Novartis Investigative Site
    San Isidro, Lima region 27, Peru
  • Novartis Investigative Site
    Moscow, 115478, Russia
  • Novartis Investigative Site
    Saint Petersburg, 197758, Russia
  • Novartis Investigative Site
    Jeonju, Jeollabuk-do 561-712, South Korea

Showing the first 100 of 122 sites across 22 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Ohtsu A, Ajani JA, Bai YX, Bang YJ, Chung HC, Pan HM, Sahmoud T, Shen L, Yeh KH, Chin K, Muro K, Kim YH, Ferry D, Tebbutt NC, Al-Batran SE, Smith H, Costantini C, Rizvi S, Lebwohl D, Van Cutsem E. Everolimus for previously treated advanced gastric cancer: results of the randomized, double-blind, phase III GRANITE-1 study. J Clin Oncol. 2013 Nov 1;31(31):3935-43. doi: 10.1200/JCO.2012.48.3552. Epub 2013 Sep 16. PubMed 24043745 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2009, a primary completion of Jan 2014 and a completion of Jan 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2015, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 8, 2009
First posted
Apr 10, 2009
Start
Jul 2009
Primary completionActual
Jan 2014
CompletionActual
Jan 2014
Results first posted
Apr 6, 2015
Last update
Nov 3, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 3, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00879333
Responsible party
Sponsor
First posted
Apr 10, 2009
Start date
Jul 2009
Primary completion
Jan 2014
Completion
Jan 2014
Results posted
Apr 6, 2015
Last update
Nov 3, 2015

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Everolimus

Start the discussion